Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease
- 27 September 2005
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 65 (6), 941-943
- https://doi.org/10.1212/01.wnl.0000176071.08694.cc
Abstract
Among 27 preclinical carriers of the Huntington disease mutation (PMC), the authors found normal striatal values for MRI volumetry in 88% and for fluorodesoxyglucose PET metabolic index in 67%. Raclopride PET binding potential (RAC-BP) was decreased in 50% and correlated with increases in the product of age and CAG repeat length (p < 0.0005). Dopamine D2 receptor availability measured by RAC-BP seems the most sensitive indicator of early neuronal impairment in PMC.Keywords
This publication has 10 references indexed in Scilit:
- Onset and rate of striatal atrophy in preclinical Huntington diseaseNeurology, 2004
- Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET studyBrain, 2003
- Clinical markers of early disease in persons near onset of Huntington’s diseaseNeurology, 2001
- Quantitative neuropathological changes in presymptomatic Huntington's diseaseAnnals of Neurology, 2001
- Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's DiseaseCell, 2000
- Association Between Age-Related Decline in Brain Dopamine Activity and Impairment in Frontal and Cingulate MetabolismAmerican Journal of Psychiatry, 2000
- Experimental Therapeutics of Neurodegenerative Disorders: Unmet NeedsScience, 1998
- Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's diseaseAnnals of Neurology, 1997
- CAG repeat number governs the development rate of pathology in Huntington's diseaseAnnals of Neurology, 1997
- Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's diseaseBrain, 1996